Ivabradine

A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE.

Also Known As:

7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; Corlanor; S 16257; S 16257-2; S 16260-2; S-16257; S-16257-2; S-16260-2; S 16257 2; S 162572; S 16260 2; S 162602; S16257; S162572; S162602; 2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-

Networked: 1020 relevant articles (189 outcomes, 296 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Ivabradine: 1020

Experts

1.	Böhm, Michael: 45 articles (01/2019 - 01/2007)
2.	Ford, Ian: 44 articles (12/2019 - 12/2005)
3.	Komajda, Michel: 40 articles (12/2019 - 01/2010)
4.	Borer, Jeffrey S: 39 articles (12/2019 - 02/2003)
5.	Tavazzi, Luigi: 35 articles (12/2019 - 06/2008)
6.	Swedberg, Karl: 33 articles (12/2019 - 01/2010)
7.	Tardif, Jean-Claude: 24 articles (01/2020 - 12/2005)
8.	Ferrari, Roberto: 17 articles (04/2019 - 05/2006)
9.	Fox, Kim: 17 articles (01/2019 - 02/2003)
10.	Imamura, Teruhiko: 14 articles (07/2022 - 10/2020)

Related Diseases

1.	Heart Failure 01/01/2023 - "Ivabradine and β-blockers can provide more pronounced clinical improvement in most chronic coronary syndromes and heart failure with reduced ejection fraction patients with a fixed-dose combination providing an opportunity to improve adherence." 03/24/2017 - "Conclusions: Ivabradine significantly reduced heart rate and improved the clinical outcomes and NYHA function class in Chinese patients with chronic heart failure, these beneficial effects are achieved without inducing remarkable adverse reactions.The" 11/01/2021 - "Obtaining a more optimal heart rate with ivabradine in patients with congestive heart failure is reflected in an improvement in NYHA classification." 10/01/2023 - "Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)." 02/26/2017 - "From the available clinical trials, ivabradine + beta-blocker resulted in a significantly greater reduction in HR coupled with improvement in combined end-point of heart failure readmission and cardiovascular death but with no improvement in all cause or cardiovascular mortality. "
2.	Stable Angina 11/01/2014 - "Clinical trials have proven the anti-anginal and anti-ischemic efficacy of the pacemaker current inhibitor ivabradine in combination with beta-blockers in patients with stable angina pectoris (AP). " 04/01/2017 - "However, the combination of ivabradine and beta-blockers has proven efficacy in patients with stable angina pectoris. " 01/01/2017 - "Ivabradine addition on top of optimal individualized dose of β-blockers is associated with decreased anginal events and improvement in QOL in patients with stable angina and history of coronary revascularization." 04/01/2016 - "Control group type did not influence the effect of exercise duration (significant) or time to angina onset (significant).Compared with beta-blocker and placebo, ivabradine improved exercise duration and time to onset of angina in patients with stable angina. " 12/01/2011 - "Beta-blocker dose up-titration or addition of ivabradine in stable angina: more is not necessarily better : editorial to: "efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina" by E. "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 10/01/2009 - "Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. " 05/27/2009 - "Ivabradine is a new efficient and safe therapeutic option in the treatment of coronary artery disease. " 12/15/2016 - "This review provides current information regarding the safety and efficacy of HR reduction with ivabradine in clinical studies involving >36,000 patients with chronic stable coronary artery disease and >6,500 patients with systolic HF. " 03/01/2018 - "Ivabradine has been extensively evaluated for coronary artery disease wherein (2) large trials was shown to have no mortality benefit. " 01/01/2017 - "Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study."
4.	Sinus Tachycardia 01/01/2009 - "The results of our study show that patients with inappropriate sinus tachycardia can be successfully treated with ivabradine." 10/09/2012 - "In this cohort, ivabradine significantly improved symptoms associated with inappropriate sinus tachycardia and completely eliminated them in approximately half of the patients. " 12/01/2010 - "Ivabradine appears effective and safe in patients with symptomatic inappropriate sinus tachycardia." 08/01/2012 - "The safety and efficacy of ivabradine applied in heart transplant (HTx) recipients with permanent sinus tachycardia (PST) has been depicted in previous short-term follow-up studies. " 09/01/2010 - "Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia."
5.	Tachycardia (Tachyarrhythmias) 01/01/2016 - "In our group of patients with congenital JET, adjunctive treatment with ivabradine resulted in effective and safe rhythm/heart rate control and therefore may be recommended early in the course of this rare inborn tachyarrhythmia." 03/01/2022 - "Thus, ivabradine can be an effective treatment for re-entrant atrial tachycardia." 03/01/2022 - "Ivabradine is an effective treatment for focal atrial tachycardia. " 05/01/2015 - "We suggest that ivabradine might be therefore useful in the treatment of supraventricular tachyarrhythmias due to an enhanced automaticity. " 05/01/2023 - "This study investigated the efficacy of ivabradine monotherapy in pediatric patients with focal atrial tachycardia (FAT). "

Related Drugs and Biologics

1.	Metoprolol (Toprol-XL)
2.	Atenolol (Tenormin)
3.	Bisoprolol (Concor)
4.	Carvedilol (Coreg)
5.	Mineralocorticoid Receptor Antagonists
6.	Nitrates
7.	NG-Nitroarginine Methyl Ester (L-NAME)
8.	Reducing Agents
9.	Cytokines
10.	Ranolazine

Related Therapies and Procedures

1.	Therapeutics
2.	Patient Readmission
3.	Contraindications
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Resuscitation